bluebird gene therapy

high-flying bluebird bio sells itself to private equity

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Reuters on MSN · 1d

Gene therapy maker bluebird to go private in discounted deal amid cash crunch

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch.

BioPharma Dive · 1d

Bluebird, at risk of default, agrees to take-private deal

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth.

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...

Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy

In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...

FiercePharma1d

Once valued at $10B, bluebird bio sold to private equity firms for $29M

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

STAT1d

Pharmalittle: We’re reading about RFK Jr. targeting CDC and FDA advisers, a Pfizer gene therapy, and more

HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who advise the government on vaccine approvals ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results